Lectin staining and Western blot data showing differential sialylation of nutrient-deprived cancer cells to sialic acid supplementation  by Badr, Haitham A. et al.
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 5 (2015) 481–488http://d
2352-34
(http://c
DOI
n Corr
nn Cor
E-mjournal homepage: www.elsevier.com/locate/dibData ArticleLectin staining and Western blot data showing
differential sialylation of nutrient-deprived
cancer cells to sialic acid supplementation
Haitham A. Badr a, Dina M.M. AlSadek b, Mohit P. Mathew c,
Chen-Zhong Li d, Leyla B. Djansugurova e, Kevin J. Yarema c,n,
Haﬁz Ahmed f,nn
a Department of Biochemistry, Faculty of Agriculture, Zagazig University, Zagazig 44511, Egypt
b Department of Histology and Cytology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt
c Department of Biomedical Engineering and Translational Tissue Engineering Center, The Johns Hopkins
University, 400 North Broadway Street MD, Baltimore 21231, USA
d Department of Biomedical Engineering, Florida International University, 10555 West Flagler Street, Miami,
FL 33174 USA
e Institute of General Genetics and Cytology, Al-Farabi Ave, 93, Almaty 050060, Kazakhstan
f Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine and Institute
of Marine and Environmental Technology, 701 East Pratt Street, Baltimore, MD 21202, USAa r t i c l e i n f o
Article history:
Received 12 August 2015
Received in revised form
26 September 2015
Accepted 29 September 2015
Available online 9 October 2015
Keywords:
Differential sialylation
Aberrant glycosylation
Sialic acid biosynthesis
Nutrient deprivation
Metabolic glycoengineering.x.doi.org/10.1016/j.dib.2015.09.043
09/& 2015 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
espondence to: 5029 Smith Building, 400
respondence to: GlycoMantra, Inc., 1450 S
ail addresses: kyarema1@jhu.edu (K.J. Yarea b s t r a c t
This report provides data that are speciﬁcally related to the differential
sialylation of nutrient deprived breast cancer cells to sialic acid sup-
plementation in support of the research article entitled, “Nutrient-
deprived cancer cells preferentially use sialic acid to maintain cell
surface glycosylation" [1]. Particularly, breast cancer cells, when sup-
plemented with sialic acid under nutrient deprivation, display sialy-
lated glycans at the cell surface, but non-malignant mammary cells
show sialylated glycans intracellularly. The impact of sialic acid sup-
plementation under nutrient deprivation was demonstrated by mea-
suring levels of expression and sialylation of two markers, EGFR1 and
MUC1. This Data in Brief article complements the main manuscript by
providing detailed instructions and representative results for cell-level
imaging and Western blot analyses of changes in sialylation during
nutrient deprivation and sialic acid supplementation. These methodsvier Inc. This is an open access article under the CC BY license
/j.biomaterials.2015.08.020
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H.A. Badr et al. / Data in Brief 5 (2015) 481–488482can be readily generalized for the study of many types of glycosylation
and various glycoprotein markers through the appropriate selection of
ﬂuorescently-labeled lectins.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations TableSubject area Biologyore speciﬁc sub-
ject areaNutrient deprivation, cell surface glycosylationype of data Cell images, Western blot
ow data was
acquiredImaging cells on DV elite imaging system from Applied Precision (Applied Pre-
cision, USA).
Western blotting using chemiluminescent substrate (Pierce™ Fast Western Blot
Kit and ECL Substrate from Thermo Fisher Scientiﬁc Inc.).ata format Filtered images for cell images, data for Western blot
xperimental
factorsCells were grown on the surface of a cover slip and the adherent cells were ﬁxed
with 70% ice-cold ethanol. After ﬂuorescent-labeled lectin staining, cells were
further treated with Ribonuclease A and the nuclei were counter stained with
TO-PRO-3.
The protein expression and sialylation of EGFR and MUC1 was examined by
Pierce ECL Western Blotting system.xperimental
featuresCells were stained with different FITC-labeled lectins and the nuclei were counter
stained with TO-PRO-3. Images were captured on DV elite imaging system and
merged using softWoRx DMS from Applied Precision (Applied Precision, USA).
Protein extracts of cells were immunoprecipitated and immunoprecipitated
proteins were subjected to Western blotting.ata source
locationThe Delta Vision Elite Imaging System Core Facility at Herbert Wertheim College
of Medicine, Florida International University.
Immunoprecipitation and Western blotting were performed at Florida Interna-
tional University and Zagazig University.ata accessibility The data are provided in this article.D
Value of the data
 The supplementation with sialic acid (Neu5Ac) resulted in higher expression of Neu5Ac on cancer
cells than normal cells. In cancer cells, the expression of Neu5Ac was notably on the cell surface,
whereas in normal cells expression of Neu5Ac was intracellular.1. Data
The data show that cancer cells under nutrient deprivation conditions use sialic acid to maintain
cell surface glycosylation and surface glycan display.
1.1. Neu5Ac treatment of nutrient deprived cancer cells enhances sialylation at the cell surface
Supplementation of breast cancer cells (T47D, MCF7, and MDA MB231) and normal mammary cells
(MCF10A and HB4A) to 10 mM sialic acid (Neu5Ac) under nutrient deprivation for 2 h (optimization of
treatment condition described in the main article [1]) resulted enhanced sialylation as quantitated by
H.A. Badr et al. / Data in Brief 5 (2015) 481–488 483binding with WGA (speciﬁc for Neu5Ac), SNA (speciﬁc for Neu5Ac-α2,6Gal), and MAL-I (speciﬁc for
Neu5Ac-α2,3Gal) using ﬂow cytometry of the permeabilized cells [1,2]. Interestingly, the enhanced
sialylation of the nutrient deprived cells upon sialic acid supplementation was more pronounced in
the cancer cells (1.5-to-2.8-fold) compared to the normal cells (1.4-to-1.5-fold). The increased lectin
binding to the Neu5Ac-supplemented, nutrient-deprived cells was corroborated by confocal micro-
scopy. Consistent with the ﬂow cytometry data, FITC-conjugated WGA, SNA, and MAL-I lectins
showed enhanced ﬂuorescence signal for both normal and cancer cells after sialic acid treatment [1].
Interestingly, MAL-I staining in the treated normal cells was distributed throughout the Golgi as
demonstrated by co-localization with the Golgi marker GM130, but in the malignant cells this lectin
was located almost exclusively on the cell surface [1] (see also DIB Fig. 1A and B). In contrast, control
experiments where both normal and malignant cells treated with Neu5Ac (10 mM for 48 h) in
complete medium showed only minimal enhancement (e.g., 6–28%) of lectin binding (Figure S3 in
Ref. [1]).
1.2. Neu5Ac treatment of nutrient deprived cancer cells increases the expression and sialylation of EGFR
and MUC1
To explore the importance of sialic acid supplementation of nutrient-deprived cells on speciﬁc
membrane glycoproteins, two cell surface receptors (EGFR and MUC1) were chosen because of their
important roles in promoting tumor growth and metastasis. To determine whether EGFR and MUC1
were over-expressed, over-sialylated, or both, EGFR and MUC1 were immuno-precipitated and analyzed
by Western blot analysis using commercial antibodies that recognized the un-glycosylated form of each
protein. The anti-MUC1 antibody recognizes an epitope corresponding to the tandem repeat region of
MUC1and detects only one band in MCF7 cell line (Product Data Sheet, Santa Cruz) as well as in other
cell lines (Personal Communication, Santa Cruz Technical Service). Anti-EGFR antibody also detected
only one band. Negative control experiment for each antibody did not result in any band (data not
shown). As shown in DIB Fig. 2A, anti-MUC1 and anti-EGFR antibodies immuno-precipitated increased
amounts of MUC1 and EGFR frommalignant cell lysates compared to the normal cells. The higher levels
of MUC1 and EGFR immunopuriﬁed by antibodies that recognize protein epitopes of these glycopro-
teins was consistent with qRT-PCR results where mRNA levels of these two proteins in nutrient-
deprived cells supplemented with sialic acid were compared to the untreated cells (Figure S4 in Ref.
[1]). Moreover, MUC1 and EGFR puriﬁed from the Neu5Ac treated malignant cells were more heavily
sialylated (based on slower migration observed during SDS-PAGE) compared to those from the
untreated cells (both normal and malignant) as well as treated normal cells, an effect that was reversed
by sialidase treatment (DIB Fig. 2A). To further corroborate the increased sialylation of these cancer
markers, equal amounts of immunoprecipitated MUC1 and EGFR were precipitated with MAL-I and
subjected to Western blot analysis followed by immunodetection that again showed that the malignant
cells migrated slower during SDS-PAGE consistent with increased sialylation (DIB Fig. 2B). As expected,
negligible or no bands were observed when immunopuriﬁed MUC1 and EGFR were ﬁrst sialidase-
treated and then precipitated with MAL-I (DIB Fig. 2B). The increased sialylation of MUC1 and EGFR was
a least in part due to α2-3 sialic acids because these immunoprecipitated glycoproteins were further
precipitated by MAL-I. To conﬁrm MAL-I speciﬁcity towards Neu5Acα2-3Gal, equal amounts of
desialylated immunoprecipitated glycoproteins (asialoMUC1 and asialoEGFR) were precipitated with
MAL-I and subjected to Western blot followed by immunodetection (DIB Fig. 2B).2. Experimental design, materials and methods
2.1. Materials
Sialic acid (N-acetyl-5-neuraminic acid, Neu5Ac) was obtained from Santa Cruz Biotechnology
(USA). Ribonuclease A, insulin, and hydrocortisone were purchased from Sigma-Aldrich (USA).
RPMI1640 medium (ATCC modiﬁcation), HEPES buffer, fetal bovine serum (FBS), and TO-PRO-3 were
purchased from Life Technologies Corporation (USA). Phosphate-buffered saline (PBS, 137 mM sodium
Fig. 1. (A) MAL-I lectin staining followed by cell imaging. Cells were treated for 2 h in the presence of Neu5Ac (10 mM) under
nutrient deprivation and stained for 30 min with FITC-labeled MAL-I lectin at concentration of 5 mg/mL (green ﬂuorescence).
Cells were further treated with 1 mg/ml RNase A and the nuclei were counter-stained with TO-PRO-3 (red ﬂuorescence), Images
are shown at 15 mm magniﬁcation. The white arrow represents MAL-I binding of cell surface glycans. © The Delta Vision Elite
Imaging System Core Facility at Herbert Wertheim College of Medicine, Florida International University, Miami (File date: 13-
12-2012). (B) Blow up of MAL-I staining of MDA MB231 cancer cell showing cell surface glycan sialylation (green region).
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phate, pH 7.5) was obtained from Technova (USA). FITC conjugates of Maackia amurensis agglutinin I
(MAL-I, speciﬁc for Neu5Ac-α2,3Gal) [3], Sambucus nigra agglutinin (SNA, speciﬁc for Neu5Ac-
α2,6Gal), Triticum vulgaris agglutinin (WGA, which recognizes Neu5Ac and GlcNAc) were obtained
from Vector Laboratories (USA). All other chemicals were purchased from Sigma-Aldrich in analytical
grade quality.2.2. Cell lines and culture conditions
Human normal mammary epithelial cell lines MCF10A and HB4A and breast cancer cell lines T47D,
MCF7 and MDA MB231 (American Type Culture Collection, USA) were cultured in 175 cm2 ﬂasks in
RPMI1640 medium (without added antibiotics to avoid sialyltransferase inhibition [1,4]), supple-
mented with 1% FBS (the low level of FBS was used to minimize interference from sialic acid sca-
venged from serum components such as BSA) at 37 °C under 5% CO2. For normal cells, the medium
also contained 10 mg/mL insulin and 5 mg/mL hydrocortisone. For all experiments, MCF10A, HB4A,
T47D, MCF7 and MDA MB231 cells were used within the ﬁrst three passages, incubated 72 h to reachFig. 2. Examination of sialylation of MUC1 and EGFR on normal and malignant cells after sialic acid treatment under nutrient
deprivation. (A) Equal amount (100 μg) of each cell extract was subjected to immuno-precipitation with anti-MUC1 and anti-
EGFR antibodies and the precipitated proteins were subjected to Western blot and immuno-detection with the respective
antibody. In parallel, equal amount of each crude protein extract was desialylated and similar precipitation was carried out.
Please note, both MUC1 and EGFR puriﬁed from the Neu5Ac treated cancer cells (T47D, MCF7, and MDA MB231) moved slower
on SDS-PAGE compared to the normal cells (MCF10A and HB4A), but this effect was reversed by sialidase treatment (see
corresponding lower panel) suggesting that MUC1 and EGFR from the Neu5Ac treated cancer cells were more sialylated
compared to those from the normal cells. (B) Equal amount of immuno-precipitated proteins (MUC1 and EGFR) as described
above was subjected to MAL-I precipitation and detected on Pierce ECL Western Blotting as described in Materials and
Methods. As expected, negligible or no bands were observed when immunopuriﬁed MUC1 and EGFR were ﬁrst sialidase-
treated to remove sialic acid and then precipitated with MAL-I (corresponding lower panel). As MAL-I binds α2-3-sialylated
glycoproteins, no precipitation occurred with sialidase treated MUC1 and EGFR.
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EDTA, 154 mM NaCl, and 10 mM N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES), pH
7.4 for o5 min at 37 °C.
2.3. Nutrient deprivation and Neu5Ac treatment
Protocol for nutrient deprivation of cells in suspension: Step 1, cell cultures were harvested as
described above. Step 2, cells were resuspended in serum-free RPMI-1640 medium and pelleted by
centrifugation at 900g for 5 min; during this step cells experience 10 min of nutrient deprivation in
serum-free media without Neu5Ac. Step 3, the cells were rinsed twice in 37 °C PBS by centrifugation
for 5 min and 1 mL aliquots of 1104 cells were pipetted gently into 15 mL BD Falcon tubes; during
this step the cells experience an additional 20 min of nutrient-deprivation. Step 3, cell suspension
aliquots corresponding to 104 cells mL1 were equilibrated in tubes containing Neu5Ac-PBS buffer by
placing the tubes with opened caps for 60 min in a humidiﬁed incubator at 37 °C and 5% CO2 with
continuous shaking at 30 strokes per minute; during this Neu5Ac-supplementation step, negative
controls were maintained in non-supplemented PBS. Step 4, the Neu5Ac-PBS solution was decanted,
the tubes were gently tapped to loosen the gravity-pelleted cells, and then rinsed twice in warm
(37 °C) PBS followed by pelleting by 5 min of centrifugation each time; this process provided an
additional 30 min of nutrient-deprivation in the absence of supplemental Neu5Ac. The entire 5 step
process results in 2 h of nutrient deprivation, after which the cells were analyzed by the methods
listed below with the exception of the lectin staining which used cells that were nutrient-deprived
under adherent conditions. Protocol for nutrient deprivation of adherent cells: Step 1, cells were cul-
tured on sterile glass microscope cover slips for two days. Step 2, the cover slips were placed in a
sterile plastic rack in warm (37 °C) PBS buffer for 30 min, then the PBS was replaced with Neu5Ac-PBS
solution for 60 min to provide Neu5Ac supplementation (controls were maintained in non-
supplemented PBS), and then the cell-laden cover slips were placed back in PBS buffer for 30 min.
All incubations were performed in a humidiﬁed incubator at 37 °C and 5% CO2 with continuous
shaking at 30 strokes per minute. Overall this process mimics the non-adherent treatment conditions
with respect to the duration of nutrient-deprivation (2 h total) and Neu5Ac supplementation
(60 min). In addition to the nutrient-deprivation protocols, “nutrient-happy” control experiments
were performed where the cells were maintained in serum containing medium and treated with
Neu5Ac (or not for the Neu5Ac(-) controls) as described above.
2.4. Flow cytometry analysis
For this purpose, cells were ﬁxed by suspending them in 70% (v/v) ethanol and stored at 4 °C for
15 min, washed twice with cold PBS, and then placed in 96-well plates (1104 cells per well) [1]. The
cells were then stained with the ﬂuorescein isothiocyanate-labeled lectins (SWGA, WGA, SNA and
MAL-I). For the comparison of mean ﬂuorescence intensities, the instrument settings for ﬂuorescence
and compensation were the same for all experiments. Data were collected from at least 10,000 cells
for each sample.
2.5. Cell viability assay
Cells were harvested as described above without ﬁxation. Cell pellets were resuspended in PBS
supplemented with 1 mg/mL propidium iodide (PI) and incubated for 5 min at ambient temperature
[1,2]. Cells were analyzed by ﬂow cytometry on BD Accuri C6 ﬂow cytometer with CFlow Plus
operating software (BD Biosciences, USA). The proportion of dead and living cells was determined as
the percentage of PI-stained cells. The MTT assay was used to measure changes in cell viability and
proliferation for 5 days after returning the Neu5Ac-treated and untreated cells to the complete
medium. The formazan dye produced after DMSO solubilization was quantiﬁed at 560 nm using a
multiwell scanning spectrophotometer (Bio-Rad, USA).
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Cells were grown on the surface of a cover slip and the adherent cells were ﬁxed with 70% ice-cold
ethanol for 15 min [1,2]. After washing with PBS, cells were stained with different FITC-labeled lectins
(5 mg/mL) for 1 h. After staining, cells were further treated with Ribonuclease A (10 mg/mL) and the
nuclei were counter stained with TO-PRO-3. Images were captured on DV elite imaging system and
merged using softWoRx DMS from Applied Precision (Applied Precision, USA).2.7. Immuno-precipitation and lectin-precipitation followed by Western blotting
Cells were lysed in Triton X-100 lysis buffer (10 mM Tris–HCl [pH 8.0], 5 mM ethylenediamine-
tetraacetic acid, 320 mM sucrose, 1% Triton X-100, 1 mM PMSF, 2 mM DTT, 1 mg/mL leupeptin, 1 mg/mL
aprotinin) and then incubated on ice for 15 min [1]. Following centrifugation, the supernatant was
collected and protein concentrations were determined by BCA protein assay kit (Pierce). For immuno-
precipitation, each cell extract (100 mg of total protein) was incubated with 1 mg of either anti-MUC1
antibody [Mucin1 (sc-7313 Santa Cruz)] or anti-EGFR antibody [epidermal growth factor receptor
(EGFR 2232 Cell Signaling)]. The precipitated protein was subjected to SDS-PAGE and Western blot-
ting onto PVDF membranes (Pierce). The blots were then probed with the corresponding primary
antibodies followed by secondary antibody-horseradish peroxidase (HRP) conjugate (Santa Cruz) and
signals were detected by ECL system (Pierce). Negative control includes PBS instead of primary
antibody. For β-Actin control, anti-β-Actin antibody from Santa Cruz (sc-47778) was used. For pre-
cipitation of α2-3-sialylated glycoproteins with MAL-I, equal amount of immunoprecipitated MUC1
and EGFR was incubated with 1 μg lectin. The precipitated protein was separated on SDS-PAGE fol-
lowed by Western blot detection with anti-MUC1 and anti-EGFR antibodies as described above.
Immuno- or lectin-precipitation experiments were also performed with the desialylated crude pro-
tein extract (for immunoprecipitation) or immunopuriﬁed MUC1 and EGFR (for MAL-I precipitation)
and similar blots were prepared. For desialylation, the cell extract was incubated with neuraminidase
(100 mU/mL) for 1 h at 37 °C.Competing ﬁnancial interests
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